Find trials
Search tips

Determinants of Incident Stroke Cognitive Outcomes and Vascular Effects on Recovery (DISCOVERY)

Overview

About this study

The purpose o fthis study

A total of 8,000 patients presenting to CPSs with acute-onset AIS, ICH or aSAH and no history of dementia will be enrolled within 6 weeks of stroke onset.

All participants will undergo baseline screening for evidence of pre-stroke dementia. Those who pass baseline screening will complete a blood draw and a series of cognitive and functional assessments at baseline.

Participants will undergo in-person (3-6 months, 18 months) and telephone (annual) follow-up visits for the duration of the study to assess for longitudinal cognitive and functional outcomes. In addition to Tier 1 procedures, at each in-person follow-up visit: Tier 2 participants will also undergo MRI scanning, comprehensive cognitive assessment batteries and longitudinal blood collection; and Tier 3 participants will also complete amyloid- and tau-PET/CT scans.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Age ≥ 18 years old.
  • Admitted to the hospital with a diagnosis of AIS, ICH, or aSAH.
  • Radiographic confirmatory evidence of: (1) AIS, (2) non-traumatic ICH or (3) non-traumatic acute aSAH.
  • Able to complete baseline visit in person or by phone within 6 weeks of stroke onset.
  • Able to provide informed consent by self or via proxy.
  • Fluent in English or Spanish prior to stroke onset.

Exclusion Criteria:

  • Documented history of pre-stroke dementia or fails dementia pre-screen.
  • Concurrent enrollment into a study that is not approved under the DISCOVERY Co-Enrollment Policy.
  • Unable to complete study protocol (advanced directives such as comfort measures only, or inability to complete the study due to severe medical/behavioral co-morbidities), as determined by physician investigator during screening process.
  • Contraindication to MRI.
  • Women who are pregnant or seeking to become pregnant.
  • History of risk factors for torsade de pointes or taking medications known to prolong QT interval.
  • Known to have a genetic condition which can increase the risk of developing cancer.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Eugene Scharf, M.D.

Open for enrollment

Contact information:

Amy Headlee CCRP, SOCRA

(507) 422-0406

Headlee.Amy@mayo.edu

More information

Publications

Publications are currently not available

More about research at Mayo Clinic

.
CLS-20516798

Mayo Clinic Footer